Modeling how exposure to efpeglenatide builds tolerance to nausea and vomiting over time to guide dose increases

Nausea or vomiting are common adverse events associated with glucagon-like peptide-1 receptor agonists, which may decline over time with continued use.

• Tolerance to nausea or vomiting may develop in patients receiving efpeglenatide.
• Longitudinal dynamics of these adverse events have not been quantitatively characterized until now.
• The study focuses on non-diabetic patients with obesity.
• Repeated time-to-event modeling is utilized to analyze efpeglenatide-induced nausea and vomiting.
• Findings could inform future dose-escalation strategies.

Simplified